Biodexa Pharmaceuticals Plc (BDRX)
0.775
-0.01
(-0.74%)
USD |
NASDAQ |
Sep 02, 16:00
0.7604
-0.01
(-1.88%)
After-Hours: 20:00
Biodexa Pharmaceuticals Research and Development Expense (Annual) : 5.026M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 5.026M |
| December 31, 2024 | 6.679M |
| December 31, 2023 | 4.744M |
| December 31, 2022 | 5.906M |
| December 31, 2021 | 6.401M |
| December 31, 2020 | 7.781M |
| December 31, 2019 | 10.01M |
| Date | Value |
|---|---|
| December 31, 2018 | 12.48M |
| December 31, 2017 | 10.73M |
| December 31, 2016 | 8.995M |
| December 31, 2015 | 9.03M |
| December 31, 2014 | 8.955M |
| December 31, 2013 | 3.009M |
| December 31, 2012 | 2.616M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| NuCana Plc | 16.79M |
| Mereo BioPharma Group Plc | 17.81M |
| BioNTech SE | 2.376B |
| Silence Therapeutics Plc | 60.29M |
| Autolus Therapeutics Plc | 128.59M |